MX2007000103A - Bibliotecas de anticuerpos universales. - Google Patents

Bibliotecas de anticuerpos universales.

Info

Publication number
MX2007000103A
MX2007000103A MX2007000103A MX2007000103A MX2007000103A MX 2007000103 A MX2007000103 A MX 2007000103A MX 2007000103 A MX2007000103 A MX 2007000103A MX 2007000103 A MX2007000103 A MX 2007000103A MX 2007000103 A MX2007000103 A MX 2007000103A
Authority
MX
Mexico
Prior art keywords
derived
antibody libraries
libraries
universal antibody
sequences
Prior art date
Application number
MX2007000103A
Other languages
English (en)
Inventor
Roberto Crea
Original Assignee
Bioren Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioren Inc filed Critical Bioren Inc
Publication of MX2007000103A publication Critical patent/MX2007000103A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se describen bibliotecas de anticuerpo universal las cuales son sinteticas y se derivan de las secuencias de anticuerpo humanas expresadas seleccionadas de acuerdo a ciertos criterios, por ejemplo que las secuencias sean derivadas de anticuerpos de ocurrencia natural expresados en respuesta a cierta clase de antigeno (por ejemplo, moleculas pequenas, polisacaridos, peptidos o proteinas) y teniendo regiones CDR construidas para una mejor diversidad. Tambien se describen metodos para producir y analizar dichas bibliotecas para aislamientos terapeuticos adecuados para tratar enfermedades.
MX2007000103A 2004-07-06 2005-07-06 Bibliotecas de anticuerpos universales. MX2007000103A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58593104P 2004-07-06 2004-07-06
PCT/US2005/024002 WO2006014498A2 (en) 2004-07-06 2005-07-06 Universal antibody libraries

Publications (1)

Publication Number Publication Date
MX2007000103A true MX2007000103A (es) 2007-05-11

Family

ID=35787625

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007000103A MX2007000103A (es) 2004-07-06 2005-07-06 Bibliotecas de anticuerpos universales.

Country Status (8)

Country Link
US (1) US11674240B2 (es)
EP (1) EP1781680B8 (es)
JP (1) JP5143551B2 (es)
BR (1) BRPI0513135A (es)
CA (1) CA2572961C (es)
ES (1) ES2563491T3 (es)
MX (1) MX2007000103A (es)
WO (1) WO2006014498A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
AU2014200954B2 (en) * 2006-10-02 2016-06-16 Bioassets, Llc Design and construction of diverse synthetic peptide and polypeptide libraries
CA2664681C (en) 2006-10-02 2020-07-07 Sea Lane Biotechnologies, Llc Design and construction of diverse synthetic peptide and polypeptide libraries
EP2126105A4 (en) * 2007-02-20 2010-11-03 Anaptysbio Inc SOMATIC HYPERPERMUTATION SYSTEMS
EP2173772A2 (en) * 2007-07-03 2010-04-14 Ablynx N.V. Providing improved immunoglobulin sequences by mutating cdr and/or fr positions
EP2088432A1 (en) 2008-02-11 2009-08-12 MorphoSys AG Methods for identification of an antibody or a target
CA2758356C (en) 2009-05-29 2016-07-26 Morphosys Ag A collection of vh and vl pairs having favourable biophysical properties and methods for its use
US20110053803A1 (en) * 2009-08-26 2011-03-03 Xin Ge Methods for creating antibody libraries
WO2011047146A2 (en) 2009-10-14 2011-04-21 Centocor Ortho Biotech Inc. Methods of affinity maturing antibodies
JP6253986B2 (ja) 2010-11-19 2017-12-27 モルフォシス・アーゲー コレクション及びその使用方法
CN105980557B (zh) * 2013-12-04 2020-04-07 中外制药株式会社 抗原结合能力根据化合物的浓度而变化的抗原结合分子及其文库
EP3246434A1 (en) * 2015-01-13 2017-11-22 Ewha University-Industry Collaboration Foundation Method for preparing novel antibody library and library prepared thereby
WO2017023780A1 (en) 2015-07-31 2017-02-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-drug conjugates for targeting cd56-positive tumors
EP3293293A1 (en) * 2016-09-08 2018-03-14 Italfarmaco SpA Hc-cdr3-only libraries with reduced combinatorial redundancy and optimized loop length distribution
CN111511768B (zh) * 2017-11-20 2024-03-26 南特生物科学公司 mRNA展示抗体文库和方法
US11034951B2 (en) 2017-11-20 2021-06-15 Nantbio, Inc. mRNA display antibody library and methods
KR102115300B1 (ko) 2018-06-01 2020-05-26 재단법인 목암생명과학연구소 항체 라이브러리 및 이를 이용한 항체 스크리닝 방법
WO2021115468A1 (zh) * 2019-12-13 2021-06-17 南京金斯瑞生物科技有限公司 一种构建抗体互补决定区文库的方法
US11919944B2 (en) 2020-05-11 2024-03-05 Augmenta Biosciences, Inc. Antibodies for SARS-CoV-2 and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69112207T2 (de) * 1990-04-05 1996-03-28 Roberto Chestnut Hill Mass. Crea "walk-through"-mutagenese.
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
TW373023B (en) * 1991-07-15 1999-11-01 Wellcome Found Production of antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US20030036092A1 (en) 1991-11-15 2003-02-20 Board Of Regents, The University Of Texas System Directed evolution of enzymes and antibodies
US5866344A (en) 1991-11-15 1999-02-02 Board Of Regents, The University Of Texas System Antibody selection methods using cell surface expressed libraries
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US20030194807A1 (en) 1992-11-02 2003-10-16 Roberto Crea Walk-through mutagenesis
US5922545A (en) 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
DK0859841T3 (da) 1995-08-18 2002-09-09 Morphosys Ag Protein/(poly)peptidbiblioteker
US6352842B1 (en) * 1995-12-07 2002-03-05 Diversa Corporation Exonucease-mediated gene assembly in directed evolution
CA2784251A1 (en) * 2000-12-18 2002-08-08 Dyax Corp. Focused libraries of genetic packages
EP1390741B1 (en) * 2001-04-17 2012-10-31 Abmaxis, Inc. Structure-based construction of human antibody library
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
AU2003228568A1 (en) 2002-04-17 2003-11-03 Guido Cappuccilli "doping" in walk-through mutagenesis
CA2482863A1 (en) 2002-04-17 2003-10-30 Roberto Crea Universal libraries for immunoglobulins
CN1836041A (zh) 2003-06-27 2006-09-20 比奥伦公司 浏览突变

Also Published As

Publication number Publication date
EP1781680A2 (en) 2007-05-09
US20110245108A1 (en) 2011-10-06
EP1781680B1 (en) 2016-01-20
EP1781680A4 (en) 2008-04-02
BRPI0513135A (pt) 2008-04-29
WO2006014498A3 (en) 2007-03-01
JP5143551B2 (ja) 2013-02-13
US11674240B2 (en) 2023-06-13
CA2572961C (en) 2016-08-16
ES2563491T3 (es) 2016-03-15
CA2572961A1 (en) 2006-02-09
WO2006014498A2 (en) 2006-02-09
EP1781680B8 (en) 2016-05-18
JP2008536473A (ja) 2008-09-11

Similar Documents

Publication Publication Date Title
MX2007000103A (es) Bibliotecas de anticuerpos universales.
WO2003006509A3 (en) Human mini-antibody cytotoxic for tumor cells which express the erbb2 receptor
WO2006061723A3 (en) Human monoclonal antibodies to influenza m2 protein and methods of making and using same
WO2007062245A3 (en) Human monoclonal antibody human cd134 (ox40) and methods of making and using same
WO2006113546A3 (en) Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
WO2003078600A3 (en) Human monoclonal antibodies to influenza m2 protein and methods of making and using same
WO2004018649A3 (en) Monoclonal antibodies and complementarity-determining regions binding to ebola glycoprotein
EA200700136A1 (ru) Анти-cd154-антитела
WO2009040134A8 (en) Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
AU3117201A (en) Methods and compositions for generating human monoclonal antibodies
WO2007058823A3 (en) Anti-egfr antibodies
SI1629011T1 (sl) Humane molekule za vezavo anti hu cd
MY163480A (en) Sclerostin binding agents
WO2007110678A3 (en) Neutralizing antibodies and methods of use thereof
TW200636064A (en) Anti-respiratory syncytial virus antibodies, antigens and uses thereof
WO2006118772A3 (en) Fcrn antibodies and uses thereof
WO2006113643A3 (en) High affinity fully human monoclonal antibodies to interleukin-8 and epitopes for such antibodies
WO2006084078A3 (en) Jam-3 and antibodies that bind thereto
NZ592830A (en) Process for the modulation of the antagonistic activity of a monoclonal antibody
WO2006083852A3 (en) Luca2 and antibodies that bind thereto
ATE509955T1 (de) Humanisierte kollagen-antikörper und damit verbundene verfahren
WO2006076584A3 (en) Kid31 and antibodies that bind thereto
WO2019060750A3 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
WO2005090406A3 (en) Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
UA87106C2 (uk) БІЛОК, ЯКИЙ ЗВ'ЯЗУЄ РЕЦЕПТОР Nogo

Legal Events

Date Code Title Description
FG Grant or registration